Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.
Kids lost in flooding as US endures extreme weather, from smoke up north to heat in the West
Lilly’s study enrolled people ages 60 to 85 who were in early stages of Alzheimer’s. Half received once-a-month infusions of donanemab and half dummy infusions for 18 months. How much difference does that make? It means donanemab slowed patients’ worsening by about four to seven months, the JAMA report concluded.
Chris Hemsworth is stepping back from working, for now. The 39-year-old actor told Vanity Fair he is planning to take some time off after he wraps up press for his new show “Limitless.” It's too soon to know if some patients might need to resume donanemab, said Lilly's Dr. Mark Mintun. But the amyloid “doesn't come back with any sort of vengeance,” he said, speculating that might take several years.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Eli Lilly’s experimental Alzheimer’s drug slows disease, data showAn experimental Alzheimer’s drug made by Eli Lilly slowed cognitive decline in early-stage patients, data confirmed Monday, putting it on course to be the second treatment approved within months that alters the course of the disease.
Leer más »
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the yearEli Lilly says it has applied for full FDA approval of its Alzheimer’s treatment, donanemab, and expects the agency to make a decision by the end of the year. CEO David Ricks joins SquawkStreet to discuss.
Leer más »
Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concernAnother experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, according to a study of 1,700 patients. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab.
Leer más »
Eli Lilly: Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskAnother experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.
Leer más »
Second Alzheimer’s drug to slow disease’s progression may be approved in the US this year | CNNA second drug may join the Alzheimer’s treatment Leqembi on the market by the end of the year: Eli Lilly’s donanemab. Lilly said in a news release that it had completed its US Food and Drug Administration submission for the drug, and expects regulatory action by year’s end.
Leer más »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskAnother experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after the recently approved Leqembi from Japanese drugmaker Eisai.
Leer más »